XML 51 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
As of June 30, 2024
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$1,246.8 $1,246.8 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$(1.5)$— $(1.5)$— 
Deferred consideration$12.4 $— $12.4 $— 
Contingent consideration$169.7 $— $— $169.7 
As of December 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$482.4 $482.4 $— $— 
Marketable securities$298.1 $298.1 $— $— 
Collateral for interest rate swap$6.0 $6.0 $— $— 
Liabilities
Interest rate swap$1.2 $— $1.2 $— 
Deferred consideration$5.7 $— $5.7 $— 
Contingent consideration$84.6 $— $— $84.6 
Schedule of Observable Inputs in Valuation of Deferred Consideration, Development and Regulatory Milestones and Priority Review Voucher Milestone and Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities
The following observable input was used in the valuation of the deferred consideration as of June 30, 2024:
Fair Value as of June 30, 2024 (in millions)
Observable InputInput Value
Deferred consideration
$12.4
Insmed share price as of June 30, 2024
$67.00
The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of June 30, 2024:
Fair Value as of June 30, 2024 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$161.8Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$5.2Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
16.4%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2024 and 2023 (in thousands):
Deferred
 Consideration
(Level 2 Liabilities)
Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value400 3,600 
Payments— — 
Balance as of June 30, 2023$7,800 $61,700 
Balance as of December 31, 2023$5,700 $84,600 
Additions— — 
Change in Fair Value6,700 85,100 
Payments— — 
Balance as of June 30, 2024$12,400 $169,700